Plegridy Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The plegridy market research report is one of a series of new reports that provides plegridy market statistics, including the plegridy industry's global market size, regional shares, competitors with a plegridy market share, detailed plegridy market segments, market trends and opportunities, and any further data you may need to thrive in the plegridy industry. This plegridy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising focus on personalized medicine, growth of home-based healthcare, increasing use of digital health tools, growing aging population, and rising insurance coverage. Major trends in the forecast period include digital health integration, combination therapies, advancement in drug delivery systems, telemedicine adoption, and artificial intelligence in multiple sclerosis management.

The rising prevalence of multiple sclerosis is expected to drive the growth of the plegridy market in the coming years. Multiple sclerosis is a chronic autoimmune condition where the immune system attacks the protective sheath around nerve fibers in the central nervous system, disrupting communication between the brain and the body. This leads to a variety of neurological symptoms. The increasing incidence of multiple sclerosis is due to a combination of environmental factors, improved diagnostic methods, greater awareness, and lifestyle factors such as obesity and vitamin D deficiency, particularly among women. Plegridy is used to reduce relapse rates and slow disease progression in multiple sclerosis patients by modulating the immune system. For example, in May 2024, the Multiple Sclerosis Trust in the UK reported that over 150,000 people are living with multiple sclerosis, with more than 7,100 new diagnoses each year. The number of cases has increased by up to 15% in various regions, especially among people in their 30s and 40s. As a result, the growing prevalence of multiple sclerosis is contributing to the rise of the Plegridy market.

The growth of the plegridy market is also expected to be influenced by the rise in healthcare spending. Healthcare spending covers all expenditures related to healthcare goods and services, including personal care, preventive services, and public health initiatives. The surge in healthcare spending is driven by factors such as population growth, an aging demographic, increasing chronic diseases, and rising costs for medical services and prescription drugs. Higher healthcare spending leads to greater access to treatments such as Plegridy, improves patient awareness, and strengthens healthcare infrastructure for managing multiple sclerosis. For instance, in August 2023, the National Health Service Confederation reported that the NHS England budget for the 2022-2023 fiscal year was $152.6 billion, with more than 70% allocated to integrated care boards. Therefore, the growing healthcare investment is contributing to the expansion of the Plegridy market.

The plegridy market is also benefiting from the increasing use of biologics. Biologics are complex drugs derived from living organisms, including proteins and antibodies, that target specific biological processes in the body. Their effectiveness in treating a wide range of diseases, advances in biotechnology, and a demand for more precise therapies are driving their use. Biologics have become a cornerstone in multiple sclerosis treatment, with Plegridy offering a more targeted, effective, and convenient option for patients. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported in June 2023 that pharmaceutical production in Europe grew by 4.95% in 2022, reaching $384.2 billion. This growing adoption of biologics is fueling the growth of the Plegridy market.

The key company operating in the plegridy market is Biogen Inc.

North America was the largest region in the plegridy market in 2024. The regions covered in plegridy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plegridy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Plegridy (generic name: peginterferon beta-1a) is a prescription medication used to treat relapsing forms of multiple sclerosis (MS), a chronic condition that affects the central nervous system. It helps to reduce the frequency of relapses and slows the progression of physical disability in individuals with MS.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary routes of administration for Plegridy are subcutaneous (SC) injection and intramuscular (IM) injection. Subcutaneous injection involves delivering the medication into the fatty tissue just under the skin using a short needle. This method is preferred for its convenience and gradual release of medication into the bloodstream. Patients can self-administer the medication through subcutaneous injection, making it a convenient option for managing relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). Plegridy is distributed through various channels, including direct sales, online pharmacies, and wholesale distributors, and is utilized by hospitals and clinical research laboratories.

The plegridy market consists of sales of plegridy (peginterferon beta-1a) injection and auto-injectors (plegridy pen). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.